Transrectal ultrasound for prostate cancer diagnosis and biopsy
Transrectal ultrasound (TRUS) is widely used in prostate cancer assessment. It provides a real-time view of the prostate through the rectum, helping clinicians measure the gland, locate suspicious areas and guide a biopsy needle. TRUS is chiefly a biopsy-guidance tool, not a stand-alone test that can diagnose or exclude cancer.
Most diagnostic pathways begin with a PSA blood test and digital rectal examination. An abnormal result may prompt repeat testing, risk assessment, multiparametric prostate MRI and biopsy. When tissue is required, TRUS usually supplies the access route and needle guidance, while MRI maps areas that may need extra sampling.
Ultrasound technology continues to evolve. High-frequency micro-ultrasound, elastography, contrast-enhanced ultrasound and fusion software let clinicians compare tissue features with MRI. These developments aim to improve sampling of important lesions while reducing unnecessary cores, but availability, training and evidence quality vary across Australia.
The central issue is balanced decision-making. A biopsy can clarify a diagnosis and guide treatment or active surveillance, yet it can cause bleeding, urinary retention, infection and anxiety. The appropriate strategy depends on PSA pattern, examination, MRI findings, family history, previous biopsy and medical fitness, so clear information is essential.
Why transrectal ultrasound remains clinically useful
Ultrasound's strengths are immediate and affordable. Grey-scale TRUS shows prostate size, anatomy and some lesions as darker areas. It also displays the biopsy needle within the same anatomical field as the operator's view, allowing systematic cores and targeted samples to be taken accurately.
Its limits are equally important. Many prostate cancers are invisible on TRUS, and benign calcifications can obscure the gland. A normal scan does not exclude cancer, while an unusual area may still be benign. Multiparametric MRI has greater sensitivity for clinically significant disease, so modern pathways often use MRI first and TRUS second.
Other urinary symptoms can complicate the pathway. Benign prostatic hyperplasia, prostatitis and urinary retention can influence PSA or examination findings; a review of minimally invasive BPH treatments explains how some non-cancer causes of obstruction are managed. Such conditions may coexist with cancer, so symptom relief does not remove the need for assessment.
What happens during a TRUS-guided biopsy
A biopsy starts with confirmation of consent, anticoagulant use, antibiotic plans and bowel-preparation instructions. Blood-thinning medicines should not be stopped without advice from the prescriber. Antibiotic choice and bowel preparation should follow the service's current protocol, particularly for people with diabetes, recent urinary infection or other infection risks.
For the procedure, the patient usually lies on one side with knees flexed. After local anaesthetic, gel and the ultrasound probe are inserted rectally; some men also receive sedation or a nerve block. The operator surveys the prostate, then takes cores from defined zones and any MRI-targeted area, with the number and pattern set by the clinical plan.
Afterwards, a small amount of blood in the urine or stool for a short period is common. Increasing discomfort, inability to urinate, heavy bleeding, fever or shaking chills need prompt medical assessment; severe illness or urinary retention requires urgent care. The clinician should explain recovery, warning signs and when pathology results will arrive.
Selecting cores and using advanced ultrasound
Systematic sampling remains the baseline in many services. Cores are taken across defined areas rather than only from a visible abnormality, reducing the risk that a small or poorly imaged tumour is missed. If MRI is unavailable or shows no suspicious lesion, the urologist may still recommend systematic TRUS biopsy because clinically significant cancer can be MRI-negative.
When MRI identifies a PI-RADS lesion, the usual goal is to add cores to, or sometimes replace part of, systematic sampling. Fusion software aligns MRI images with the live ultrasound picture, allowing the operator to watch the needle enter a mapped target. This can improve yield per core, but placement remains vulnerable to registration error, image quality and differences between MRI and ultrasound appearances.
Micro-ultrasound offers higher-resolution anatomy, while elastography estimates tissue stiffness. Both may help identify suspicious tissue or guide targeting, but they supplement rather than supersede MRI and pathology. Repeat biopsy may be needed after a non-diagnostic result, and men considering active surveillance may undergo additional sampling to assess disease extent.
Weighing diagnostic yield against risks
Studies of prostate biopsy use different definitions of cancer detection, significant cancer and complication rates, so headlines can be hard to compare. MRI-targeted and micro-ultrasound strategies appear promising in selected settings, but centre expertise, MRI quality and patient selection affect results. Shared decisions should compare the chance of finding clinically significant disease with infection and bleeding risks.
| Approach | Main contribution | Important limitation | Typical role |
|---|---|---|---|
| Systematic TRUS-guided cores | Broad sampling across predefined prostate zones | Can miss small or poorly visualised lesions | Common baseline, including when MRI is unavailable |
| MRI-targeted fusion biopsy | Adds or prioritises cores mapped to suspicious MRI lesions | Depends on MRI quality, registration and operator skill | Targeting selected PI-RADS 3–5 lesions in biopsy-naïve patients |
| Micro-ultrasound guidance | Shows prostate tissue at higher resolution than conventional TRUS | Limited availability and an operator learning curve | Selected centres for detection and targeted sampling |
| Elastography | Estimates tissue stiffness to support target selection | Not definitive; requires specialised equipment and training | An adjunct to MRI or systematic sampling |
No single method suits every situation. A hybrid approach can combine systematic cores with MRI-targeted samples, especially in a biopsy-naïve man with a suspicious lesion. Some centres add micro-ultrasound or elastography, while others use an established MRI fusion workflow.
The benefit of avoiding biopsy may be offset by a later, harder procedure. Conversely, extra cores without a clear purpose can increase bleeding or retention. The urologist should explain each target, expected anaesthesia and what follow-up would be appropriate if the result is benign.
Practical recommendations for access and preparation in Australia
Australia has a mixed public and private service. A GP usually refers men into a public hospital urology or radiology service, while private urologists and imaging centres provide appointments involving Medicare rebates, private health insurance or out-of-pocket gaps. Bulk-billed GP visits help with initial testing, but specialist and MRI charges can still be substantial.
Geography matters. People in Sydney, Melbourne, Brisbane, Adelaide and Perth usually have several referral options, while regional and remote patients may travel to a city centre for MRI. Fly-in, fly-out rosters, shift work and long-distance driving can make early appointments, bowel preparation and time off work difficult, so scheduling deserves attention.
Australian privacy law protects health information: the Privacy Act 1988 covers many private-sector records, while state and territory laws govern public health services. Consent must be documented. The Therapeutic Goods Administration regulates medical devices used in Australia, which matters when clinics offer newer targeting systems. Peer-reviewed specialist publishing is another quality check: the arrhythmia journal illustrates how journals separate original research, reviews and guidance, although its subject differs from urology.
Patients can reduce disruption with a few deliberate steps:
- Ask the treating service whether fasting, bowel preparation, antibiotics or a specific medication plan is required.
- Do not stop anticoagulants or other prescription medicines without instructions from the responsible clinician.
- Arrange transport, work cover and recovery time, especially if sedation is planned or the drive home is long.
- Bring PSA results, previous pathology, MRI images and reports, medication lists and relevant family history.
Making sense of results and planning next steps
The biopsy report gives the diagnosis and grade. Gleason score and ISUP Grade Group describe the cancer's histological pattern and help estimate aggressiveness. Results are interpreted with PSA, examination, MRI, positive-core count and tumour volume; a small, low-grade cancer in a low-risk context may support active surveillance rather than immediate treatment.
A diagnosis can trigger surgery, radiotherapy, androgen deprivation therapy or surveillance, but pathology is one part of that decision. Treatment may affect urinary, sexual and bowel function, so side effects deserve as much attention as cure probability. Lower-pelvic wellbeing intersects with other urological conditions; although pelvic organ prolapse techniques addresses a different, mainly female disorder, it shows why intervention should match the specific problem.
If the result is benign or inconclusive, it does not always end surveillance. The clinician may repeat PSA testing, arrange another biopsy or recommend further imaging, depending on overall risk. Any escalation should be based on the combined trend rather than a single value.
Prepare for an informed next step
If a PSA test or clinical review has raised concern, arrange a GP or urology appointment and request a clear explanation of why MRI, repeat PSA testing or biopsy is recommended. Bring prior results and a medication list, and ask what each proposed test could change. For TRUS-guided biopsy, confirm preparation, analgesia, transport and follow-up arrangements beforehand.
Patients should not be rushed into a procedure without understanding its purpose, expected yield, limitations and complications. Indefinite surveillance can also be risky when clinical factors suggest significant disease. Book the review, bring the available results and leave with a documented, evidence-based plan for further assessment.